NCT06150014 - A Clinical Study of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment Naive and Treated Patients With Chronic Hepatitis B | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 7, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

September 30, 2026

Conditions

Chronic Hepatitis b

Interventions

DRUG

Placebo

TQA3605 placebo tablets were orally administered on an empty stomach (at least 2 hours before or after meals) with warm.

DRUG

TQA3605 tablets

TQA3605 inhibits viral replication.

DRUG

Entecavir dispersible tablets

Entecavir inhibits viral replication and indicated for chronic hepatitis B treatment.

DRUG

Tenofovir disoproxil fumarate tablet

Tenofovir disoproxil fumarate is a Nucleotide reverse transcriptase inhibitor.

DRUG

Tenofovir alafenamide fumarate tablet

Tenofovir alafenamide fumarate inhibits hepatitis B virus replication.

Trial Locations (3)

The Second Affiliated Hospital of Chongqing Medical University, Chongqing

The First Affiliated Hospital of the Chinese People's Liberation Army Army Medical University, Chongqing

The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an